GYRE
Gyre Therapeutics Inc.
7.00$
+4.1%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -669.7% | -2,224.4% | -35.9% | 214.6% | -140.7% | -96.8% | 161.4% | -85.7% | -111.0% | -1,119.1% | -1,902.0% | -1,092.5% | -4,629.6% | -1,958.7% | -475,883.3% | – | -262.8% | -1,141.4% | 10.4% | 22.8% | -3.4% | 0.9% | |
| 20.5% | 68.1% | 3.0% | 7.8% | 9.0% | 7.3% | 2.3% | 2.5% | 3.8% | 15.1% | 19.4% | 26.9% | 97.5% | 17.0% | 2,483.3% | – | 0.7% | 4.0% | 1.1% | 1.0% | 1.5% | 2.1% | |
| – | – | 3,335.5% | 23,727.7% | 10.3% | 9.8% | 5.8% | 8.7% | 13.6% | 143.7% | 191.5% | 18.6% | 159.1% | 84.8% | 43,433.3% | – | 17.3% | 46.4% | 13.1% | 6.4% | 0.8% | 6.1% | |
| -40.6% | 140.2% | -48.4% | 425.9% | -0.8% | 68.7% | 241.9% | 10.6% | -17.7% | 60.9% | -351.2% | -357.7% | 209.5% | 55.7% | -22,816.7% | – | -12.3% | 6.6% | -7.6% | 6.6% | -14.8% | -13.3% | |
| 17.7% | 21.2% | 3.9% | 42.7% | 10.2% | 0.8% | 3.9% | 1.5% | 0.6% | 2.5% | 0.2% | 15.5% | 117.3% | 2.3% | 6,266.7% | – | 1.3% | 11.4% | 4.9% | 7.6% | 3.0% | 1.0% | |
| 817.6% | -21.2% | -48.2% | -227.1% | -27.5% | 39.1% | -73.3% | -59.1% | 68.8% | 369.5% | 1,867.4% | 2,134.7% | -327.8% | -1,105.3% | -1,188,683.3% | – | 46.1% | 656.7% | -13.5% | -17.4% | -18.8% | -0.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 388.1% | – | – | – | 0.0% | 44.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -4.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -91.3% | -0.5% | – | – | – | |
| 961.3% | -146.4% | 145.4% | 113.2% | 157.2% | 188.2% | 7.5% | 84.8% | -1.1% | -15.2% | 276.2% | 532.2% | 237.6% | 3,477.4% | 1,855,533.3% | – | 288.2% | 675.3% | -44.0% | 2.2% | 2.0% | 20.9% | |
| 1,109.2% | -2,392.0% | 61.3% | 100.7% | -11.0% | 130.5% | 95.6% | -60.0% | -43.3% | -764.8% | 107.3% | 1,574.4% | -4,719.8% | 413.4% | 190,966.7% | – | 71.6% | 190.6% | -4.9% | 7.3% | -20.5% | 21.7% | |
| -687.4% | -2,245.6% | -39.8% | 171.9% | -150.9% | -97.6% | 157.5% | -87.2% | -111.6% | -1,121.6% | -1,902.2% | -1,108.0% | -4,746.9% | -1,961.0% | -482,150.0% | – | -264.1% | -1,152.8% | 5.6% | 15.3% | -6.4% | -0.2% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.